Vancouver, BC – TheNewswire - June 22, 2021 - SOLARVEST BIOENERGY INC. (TSXV:SVS) ("Solarvest" or the “Company”), announces that it has amended certain stock option grants previously disclosed in its News Release of February 19, 2021. Of the 3,360,000 options granted to purchase 3,360,000 common shares of the Company, 1,400,000 options will be granted to Insiders of the Company. Subsequent to the closing of a private placement announced on April 20, 2021, there is no longer an officer and director who is also a Control Person of the Company.

The remaining information provided in the February 19, 2021 News Release remains the same.

The option grant is subject to acceptance by the TSX Venture Exchange and the Company makes no assurances that the option grant will be accepted.

About Solarvest:

Solarvest BioEnergy Inc. is an algae biotechnology company whose production platform provides it with an extremely flexible system capable of producing numerous valuable products from Organic Omega-3 fatty acids to therapeutic proteins/active ingredients. The company has successfully demonstrated (news release dated March 16th. 2015) the expression of BMP, a high value therapeutic protein, recombinant viral antigens (immune stimulating proteins), and Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.  

For further information contact:         

Email: invest@solarvest.ca

The TSX Venture Exchange has neither approved nor disapproved the contents of this news release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties.  Actual events or results could differ materially from the Company’s expectations and projections.